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Abstract
 
In chemical carcinogenesis models, GRP94 (gp96) elicits tumor-specific protective immunity.
The tumor specificity of this response is thought to reflect immune responses to GRP94-
bound peptide antigens, the cohort of which uniquely identifies the GRP94 tissue of origin. In
this study, we examined the apparent tissue restriction of GRP94-elicited protective immunity
in a 4T1 mammary carcinoma model. We report that the vaccination of BALB/c mice with
irradiated fibroblasts expressing a secretory form of GRP94 markedly suppressed 4T1 tumor
growth and metastasis. In addition, vaccination with irradiated cells secreting the GRP94 NH
 
2
 
-
terminal geldanamycin-binding domain (NTD), a region lacking canonical peptide-binding
motifs, yielded a similar suppression of tumor growth and metastatic progression. Conditioned
media from cultures of GRP94 or GRP94 NTD-secreting fibroblasts elicited the up-regulation
of major histocompatibility complex class II and CD86 in dendritic cell cultures, consistent
with a natural adjuvant function for GRP94 and the GRP94 NTD. Based on these findings,
we propose that GRP94-elicited tumor suppression can occur independent of the GRP94
tissue of origin and suggest a primary role for GRP4 natural adjuvant function in antitumor
immune responses.
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Introduction
 
GRP94 (gp96) elicits antitumor responses in prophylactic
and therapeutic immunization protocols (1–4). This phe-
nomenon, discovered by Srivastava and co-workers (1–3)
in a methylcholanthrene-elicited fibrosarcoma model, dis-
plays stringent tissue restriction. To explain the absence of
cross protection, it was proposed that GRP94 binds anti-
genic peptides, thereby endowing the protein with the
immunological identity of its tissue of origin, and can be
processed by professional APCs to yield tumor-directed
adaptive immune responses (1, 5). In support of this pro-
posal, in vitro generated complexes of GRP94 and known
peptide antigens have been demonstrated to undergo re-
ceptor-mediated uptake by APC with subsequent repre-
sentation of the GRP94-associated peptides on APC MHC
class I molecules (6–13).
In addition to its capacity to direct peptides into the class
I antigen presentation pathway, GRP94 displays the prop-
erties of a natural adjuvant in its interactions with cells of
the innate immune system. For example, GRP94 as well as
other heat shock/chaperone proteins activate nuclear factor
(NF)
 
*
 
-
 
 
 
B–mediated signal transduction and cytokine pro-
duction in APCs and importantly, promote the phenotypic
maturation of dendritic cells (DCs; 14–19). Such activities
are not dependent upon the presence of associated tumor-
specific antigens, as they occur with proteins derived from
nontumor tissues (14–19). These functions are likely rele-
vant to the ability of GRP94 to modulate immune re-
sponses, as it is now thought that the activation of innate
immunity is an essential regulatory element in the processes
leading to the generation of antigen-specific adaptive
immunity (20).
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Although it is well established that GRP94 can elicit tu-
mor suppression, the precise immunological basis for this
phenomenon, in particular the relative contribution of the
innate and adaptive components of the cellular immune re-
sponse, is unknown. We examined this question in a 4T1
murine mammary carcinoma prophylactic vaccination
model. To address the requirement for tissue restriction, ir-
radiated cells (4T1 mammary carcinoma, NIH-3T3 fibro-
blast, and KBALB fibroblast) expressing a secretory form of
GRP94 were used in the vaccination stage before challenge
with 4T1 cells. Paired vaccination studies were also per-
formed using cells (4T1 or KBALB) expressing a secretory
form of the GRP94 NH
 
2
 
-terminal geldanamycin-binding
domain (NTD), which lacks canonical peptide binding
motifs. We report that vaccination with 4T1, NIH-3T3, or
KBALB cells secreting either GRP94 or the GRP94 NTD
yielded a pronounced suppression of 4T1 tumor growth
and metastatic progression. In vitro, tissue culture superna-
tants of cells secreting GRP94 or its NH
 
2
 
-terminal domain
were a stimulus for the up-regulation of DC MHC class II
and CD86 expression. Combined, these results indicate
that GRP94-mediated tumor suppression can occur inde-
pendent of the GRP94 tissue of origin and suggest a natural
adjuvant function for GRP94 in the etiology of GRP94-
elicited antitumor immune responses.
 
Materials and Methods
 
Reagents.
 
Pro-mix ([
 
35
 
S]methionine and [
 
35
 
S]cysteine) was
obtained from Amersham Biosciences. Endoglycosidase H
(Endo H) was purchased from Boehringer. Peptide 
 
N
 
-glycosi-
dase F (PNGase-F) was purchased from New England Biolabs,
Inc. Cell culture media and reagents were from GIBCO BRL.
All other reagents were purchased from Sigma-Aldrich unless
noted otherwise.
 
Mice.
 
Female BALB/c mice (H-2
 
d
 
) were obtained from
Charles River Laboratories. Female C57BL/6 mice (H-2
 
b
 
) were
obtained from National Cancer Institute Frederick Cancer Re-
search and Development Center. Animals were maintained and
treated in strict accordance with all applicable Institutional and
Animal Care Use Committee animal care guidelines.
 
Antibodies and Cell Lines.
 
Antipeptide antiserum against
GRP94 NH
 
2
 
-terminal peptide (DU-120) was prepared according
to the protocol of Harlow and Lane (21), with antibody produc-
tion performed by contract supplier (Cocalico Biologicals).
Monoclonal antibody to the myc epitope (9E10) was purchased
from Zymed Laboratories. Antibody to prolactin was purchased
from Research Diagnostics. PE-conjugated anti–mouse I-A
 
b
 
,
CD86, GR-1, and CD11c and FITC-conjugated anti–mouse
CD40 and CD80 and appropriate isotype controls were pur-
chased from BD Biosciences. NIH-3T3 (H-2
 
q
 
), K-BALB (H-2
 
d
 
),
RAW264.7 (H-2
 
d
 
), B16-F10 (H-2
 
b
 
), and COS-7 cells were ob-
tained from American Type Culture Collection. 4T1 cells (H-2
 
d
 
)
were obtained from F. Miller, Michigan Cancer Foundation, De-
troit, MI. 4T1, NIH-3T3, K-BALB, RAW264.7, and B16-F10
cells were cultured in DME supplemented with 10% fetal calf se-
rum, 100 U/ml penicillin, and 100 
 
 
 
g/ml streptomycin. All cell
lines tested negative for mycoplasma DNA.
 
Construct Preparation.
 
Canine GRP94 cDNA was used as the
template for all PCR reactions. For GRP94
 
 
 
KDEL, the 5
 
  
 
sense
primer (5
 
  
 
GCGTCGACAGGGCCCTGTGGGTGCTG 3
 
 
 
)
and the 3
 
  
 
antisense primer (5
 
  
 
GCGCGGCCGCTCATTCAGA
TGTAGATTTCTT 3
 
 
 
) were used to prepare a PCR product
corresponding to the 5
 
  
 
2,403 bp of the GRP94 coding region
flanked by 5
 
  
 
SalI and 3
 
  
 
NotI restriction sites. The PCR product
was digested with SalI/NotI and ligated into SalI/NotI-digested
pEF/myc/cyto (Invitrogen). For GRP94 NTD, the 5
 
  
 
sense
primer (5
 
  
 
GCGTCGACAGGGCCCTGTGGGTGCTG 3
 
 
 
) and
the 3
 
  
 
antisense primer (5
 
  
 
GCGCGGCCGCTCAATTCATAAGC
TCCCAATCCCA 3
 
 
 
) were used to prepare a PCR product cor-
responding to the 5
 
  
 
1,111 bp of the GRP94 coding region
flanked by 5
 
  
 
SalI and 3
 
 
 
 NotI restriction sites. The PCR product
was digested with SalI/NotI and ligated into SalI/NotI-digested
pEF/myc/cyto vector. GRP94 NTD for recombinant expression
was prepared using the 5
 
  
 
sense primer (5
 
  
 
GGAATTCCATATG-
GACGATGAAGTCGATGTG 3
 
 
 
) and the 3
 
  
 
antisense primer (5
 
 
 
CGGATCCTCAATTCATAAGCTCCCAATCCCA 3
 
 
 
) to ob-
tain a PCR product corresponding to bp 64–1,008 of the GRP94
coding sequence, flanked by 5
 
  
 
NdeI and 3
 
  
 
BamHI restriction
sites. The PCR product was digested with NdeI/BamHI and li-
gated into NdeI/BamHI-digested pGEX vector (provided by D.
Gewirth, Duke University Medical Center, Durham, NC). Prep-
aration of the preprolactin construct has been previously de-
scribed (22).
 
Protein Expression and Purification.
 
GRP94 was purified from
porcine pancreas as previously described (23). Recombinant
GRP94 NTD protein was expressed in 
 
E. coli
 
 strain BL21 and
purified using a GSTrap affinity column (Amersham Biosciences)
according to the manufacturer’s instructions. Removal of glu-
tathione 
 
S
 
-transferase was accomplished by thrombin digestion
according to manufacturer’s instructions. Additional purification
was performed using Superdex 75 gel filtration chromatography
(Amersham Biosciences). GRP94 or recombinant GRP94 NTD
was labeled with FITC or Texas Red (TR) (Molecular Probes
Inc.) to a ratio of 2 or 3 mol dye/mol protein according to the
manufacturer’s instructions. In studies of cell surface binding and
trafficking, TR-GRP94 and FITC-GRP94 NTD were present at
equimolar concentrations.
 
Transfections.
 
All transfections were performed using Lipo-
fectamine™ reagent (GIBCO BRL) according to the manufacturer’s
instructions. Mock transfections were performed with serum-free
DME or with pEF/myc/cyto vector plus Lipofectamine™. For
the preparation of conditioned media, cells were transfected for
5 h in serum-free DME plus DNA and Lipofectamine™. Cells
were then rinsed gently with sterile PBS and transferred to DC
culture media. After 72 h of culture, media were collected and
subjected to low speed centrifugation to yield a cell-free superna-
tant fraction. These media were diluted 1:1 with fresh DC culture
media and applied to day 6 DCs, as described below.
 
Immunofluorescence.
 
4T1 cells were grown on glass coverslips
in 6-well plates overnight to 50% confluence. Cells were then
fixed in 4% paraformaldehyde in PBS for 10 min on ice, perme-
abilized in 0.1% Triton X-100 in PBS for 15 min on ice, and
blocking was performed by incubation in 1% BSA in PBS for 30
min at room temperature. For analysis of myc tag–bearing ex-
pression products, incubations were performed with a 1:200 di-
lution of anti-myc antibody in 0.1% BSA in PBS for 1 h at
room temperature. After extensive washing, bound antibodies
were labeled by incubation in a 1:200 dilution of TR-conju-
gated goat anti–mouse antibody (Cappel Laboratories) in 0.1%
BSA in PBS for 1 h at room temperature. After washing, cover-
slips were mounted onto glass slides using mounting media
(Difco Laboratories). Trafficking studies were performed using 
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thioglycollate-elicited C57BL/6 peritoneal macrophages. Mac-
rophages were adherence selected for 1 h at 37
 
 
 
C. Cell surface
binding was performed by incubation with fluorophore-labeled
proteins for 1 h at 4
 
 
 
C in RPMI plus 10% fetal calf serum. After
binding, cells were washed extensively with ice-cold RPMI.
After the final wash, cells were exchanged into prewarmed
RPMI plus 10% fetal calf serum and incubated at 37
 
 
 
C for the
indicated times. To stop transport, cells were rapidly washed in
ice-cold Hepes-buffered saline (0.8% NaCl, 25 mM K-Hepes,
pH 7.2, 1 mM CaCl
 
2
 
, 0.5 mM MgCl
 
2
 
) and fixed in 4%
paraformaldehyde in PBS for 10 min on ice. Cells were washed
again and mounted onto glass slides using mounting media
(Difco Laboratories). Confocal microscopy sections were ob-
tained using a Zeiss LSM-410 confocal microscope. All images
were processed using Adobe Photoshop
 
® 
 
Version 6.0 software.
 
Pulse-Chase Studies, Immunoprecipitation, and Glycosidase Diges-
tions.
 
24 h after transfection, cells were incubated in serum-,
methionine-, and cysteine-free DME at 37
 
 
 
C for 20 min and
then pulse labeled by incubation in serum-, methionine-, and
cysteine-free DME supplemented with 100 
 
 
 
Ci/ml [
 
35
 
S]-labeled
pro-mix at 37
 
 
 
C for 30 min. Cells were then washed and incu-
bated in chase medium (growth medium plus 1 mM unlabeled
 
l
 
-methionine) at 37
 
 
 
C for the indicated times. Samples of chase
media were collected and cleared by brief centrifugation (10 min,
15,000 
 
g
 
). Cells were lysed in ice-cold lysis buffer (150 mM
NaCl, 50 mM Tris, pH 7.5, 0.05% SDS, 1% NP-40) and cleared
by centrifugation (10 min, 15,000 
 
g
 
). Chase media and lysate
samples were precleared with normal mouse serum and Pan-
sorbin cells (Calbiochem). Proteins were immunoprecipitated
from precleared samples using anti-GRP94 (DU-120) or anti-
myc (9E10) antibodies and protein A–Sepharose beads. Immuno-
precipitates were processed for SDS-PAGE and resolved on 6,
10, or 12.5% gels. For analysis of N-linked oligosaccharide com-
position, samples were incubated in denaturing buffer (0.5%
SDS, 1% 2-mercaptoethanol) at 100
 
 
 
C for 10 min. For Endo H
digestions, denatured proteins were incubated in G5 buffer (50
mM sodium citrate, pH 5.5) with or without 5 mU Endo H at
37
 
 
 
C for 2.5 h. For PNGase-F digestions, denatured proteins
were incubated in G7 buffer (50 mM sodium phosphate, pH 7.5)
plus 1% NP-40 with or without 0.8 mU PNGase-F at 37
 
 
 
C for
2.5 h. Samples were then processed for SDS-PAGE and resolved
on 6% polyacrylamide gels. Radiolabeled proteins were visual-
ized by PhosphorImager analysis (Fuji Medical Systems) using
MacBAS-2.0
 
® 
 
software.
 
In Vivo Tumor Studies.
 
Transfected 4T1, NIH-3T3, or KBALB
cells were prepared as described above and irradiated (10,000 rad)
24 h after transfection. Irradiated cells were washed extensively with
sterile PBS and vaccination was performed by intradermal injections of
2–4 
 
  
 
10
 
6 
 
cells into the left hindlimb skin of BALB/c mice. Immuni-
zations were given weekly for four consecutive weeks. On week 5,
mice were challenged with 10
 
6 
 
4T1 cells in sterile PBS by intradermal
injection into the right back. Tumor length, width, and height were
measured every 2–3 d after challenge, and tumor volume was calcu-
lated using the following formula: Volume 
 
  
 
(
 
 
 
/6) 
 
  
 
length 
 
 
 
width 
 
  
 
height. At the completion of the study, animals were killed,
and lungs were resected and weighed. Tumors were excised and sub-
merged in 10% neutral buffered formalin solution. Paraffin embed-
ding, tissue sectioning, and histological staining with hematoxylin and
eosin were performed by the Duke University Histology Laboratory.
Statistical comparisons were performed using the Wilcoxon rank sum
test (
 
n
 
 
 
 
 
 8–10 animals).
 
Generation of Bone Marrow–derived DCs.
 
Bone marrow–derived
DCs were propagated from bone marrow progenitor cells ac-
cording to the method of Inaba et al. (24) with minor modifica-
tions. Bone marrow precursors flushed from the tibiae and femurs
of C57BL/6 mice were plated at 10
 
6 
 
cells/ml in DC culture me-
dia (RPMI 1640 plus 5% heat-inactivated fetal calf serum, 100
U/ml penicillin, 100 
 
 
 
g/ml streptomycin, 20 
 
 
 
g/ml gentamicin,
50 
 
 
 
M 2-mercaptoethanol) supplemented with GM-CSF (5%
culture supernatant from X63 cells stably transfected with murine
GM-CSF cDNA). Cultures were washed on days 2 and 4. For
maturation assays, day 6 DCs were harvested and transferred to
fresh 6-well plates at 5 
 
  
 
10
 
5 
 
cells/ml after resuspension in the
appropriate control media or conditioned media. Cells were har-
vested on day 7 and Fc receptors were blocked with Fc-block
 
®
 
reagent (BD Biosciences) before staining with antibody. After fix-
ation, cells were analyzed by flow cytometry using FACScan
 
® 
 
and
CellQuest
 
® 
 
software.
 
Cell Surface Binding Assay.
 
Cells, either adherent or in sus-
pension culture, were incubated with recombinant fluorescein-
labeled GRP94 NTD in complete media for 1 h at 4
 
 
 
C. After
washing with ice-cold media and PBS, cells were fixed with 4%
paraformaldehyde and analyzed by flow cytometry using FAC-
Scan™ and CellQuest™ software.
 
Results
 
Experimental System.
 
To date, studies on the mecha-
nism of GRP94-elicited tumor rejection have primarily
used GRP94 prepared by chromatographic fractionation of
tissue or cell homogenates. With such preparations come
concerns regarding protein purity, particularly where an
immunological response is the experimental endpoint (25–
27). This concern is especially relevant to heat shock/chap-
erone proteins, which because of their abundance, typically
undergo relatively modest enrichment (
 
 
 
20-fold) during
purification (23, 25–27). As an alternative to vaccination
with biochemically enriched GRP94 fractions, we used an
experimental system in which cells were transfected with
vectors encoding secretory forms of GRP94 and were used
as vaccines in a prophylactic immunotherapy model. By
varying the vector host tissue, we examined the hypothesis
that GRP94-mediated tumor rejection is tissue restricted.
 
Processing and Secretion of GRP94.
 
A secretory form of
GRP94 was engineered by deletion of its KDEL ER reten-
tion/retrieval sequence (28) to yield GRP94
 
 
 
KDEL. To
distinguish GRP94
 
 
 
KDEL from endogenous GRP94, a
myc tag was encoded in the COOH terminus. After trans-
fection of 4T1 breast carcinoma cells, GRP94
 
 
 
KDEL pro-
cessing and secretion was examined. As shown in Fig. 1 A,
cells expressing GRP94
 
 
 
KDEL displayed a robust ER/
Golgi staining pattern. No myc-reactive staining was ob-
served after transfection with vector alone (unpublished
data). Pulse-chase studies were performed to examine
GRP94
 
 KDEL secretion. As shown in Fig. 1 B, media
samples from GRP94 KDEL-transfected 4T1 cells con-
tained a doublet of proteins of 100 and 110 kD, recognized
by both the anti-myc and anti-GRP94 antibodies. Super-
natants of mock-transfected cells yielded neither compo-
nent (Fig. 1 B). The 100/110 kD GRP94 doublet was also
present in radiolabeled cell lysate fractions. As expected,
cell lysates of both GRP94 KDEL-transfected and mock-1450 GRP94 N-Terminal Domain Suppresses Tumor Growth and Metastasis
transfected cells contained a protein species corresponding
to endogenous GRP94 (Fig. 1 B, *).
We postulated that the presence of the 100/110 kD
doublet reflected heterogeneous oligosaccharide process-
ing of GRP94 KDEL during transit through the Golgi
apparatus. To test this hypothesis, immunoprecipitates of
chase media of cell lysates from GRP94 KDEL-trans-
fected cells were digested with Endo H or PNGase-F. As
depicted in Fig. 1 C, the protein doublet present in both
chase media and cell lysates resolved to a single protein
species upon digestion with PNGase-F (lanes 5–8). En-
dogenous GRP94 in cell lysates shifted to a higher mobil-
ity position upon PNGase-F digestion but remained dis-
tinct from GRP94 KDEL species. This difference in
mobility between GRP94 KDEL and endogenous
GRP94 likely reflects the presence of the myc tag on the
former. Endo H, an enzyme that cleaves high mannose
oligosaccharides representative of the ER and early Golgi,
did not alter the doublet present in the secreted
GRP94 KDEL, but resolved that present in the cell ly-
sates to a single species (Fig. 1 C, lanes 1–4).
Deletion of the KDEL retention/retrieval sequence of
ER resident lumenal proteins allows secretion, albeit of-
ten at markedly slower rates than that observed in bona
fide secretory proteins (29). To assess the relative rate of
GRP94 KDEL secretion, pulse-chase studies were per-
formed on 4T1 cells that had been transfected with con-
structs encoding either GRP94 KDEL or the model
secretory hormone preprolactin. As shown in Fig. 2,
GRP94 KDEL secretion is efficient, with a half-time of
2 h versus 1 h for native preprolactin. Interestingly, en-
dogenous GRP94, seen as a distinct band in immuno-
precipitates of cell lysates, remained at constant levels
over time, indicating that heterodimerization of full-
length GRP94 with GRP94 KDEL was not a signifi-
cant competing assembly reaction.
Figure 1. GRP94 KDEL is secreted by transfected 4T1 mammary
carcinoma cells. (A) Immunofluorescence with anti-myc antibody reveals
expression of GRP94 KDEL within transfected 4T1 cells. 4T1 cells
were grown on glass coverslips and stained with anti-myc antibody
(9E10) and TR-conjugated secondary antibody, and then visualized by
confocal microscopy (100 ). (B–C) Oligosaccharide processing of
GRP94 KDEL. Media or cell lysates from mock-transfected (mock) or
GRP94 KDEL-transfected (T) 4T1 cells were collected after metabolic
labeling with [35S]Promix. GRP94 species were recovered by immuno-
precipitation with either anti-GRP94 antibody or anti-myc antibody, as
indicated. GRP94 KDEL appears as a doublet of bands distinct from
endogenous, full-length GRP94 (*). (C) Glycosidase digestion of
GRP94 KDEL. Media (M) or cell lysates (C) from GRP94 KDEL-
transfected 4T1 cells were collected as described in B and then treated ( )
or not treated ( ) with Endo H or PNGase-F, as indicated. Endogenous
GRP94 in the cell lysate samples (position “E”) and transfected forms of
GRP94 are indicated (“T” positions). All samples were resolved by SDS-
PAGE on 6% gels and visualized by PhosphorImager analysis.
Figure 2. Kinetics of GRP94 KDEL secretion from 4T1 breast carci-
noma cells. (A) 4T1 cells were metabolically labeled with [35S]Promix and
then media and cell lysates were collected and immunoprecipitated with
anti-GRP94 antibody. All samples were treated with PNGase-F before
resolution by SDS-PAGE on 6% gels for GRP94 KDEL or 10% gels for
prolactin. Radiolabeled proteins were visualized by PhosphorImager anal-
ysis. (B) Bands from A were quantified using MacBAS-2.0 software and
were used to determine percent total GRP94 KDEL or prolactin present
in the media or cell lysate at each time point.1451 Baker-LePain et al.
Vaccination with GRP94 KDEL-secreting 4T1 Mammary
Carcinoma Cells or GRP94 KDEL-secreting NIH-3T3 Fibro-
blasts Suppresses 4T1 Tumor Growth. To examine the con-
tribution of the GRP94 tissue of origin to the phenome-
non of GRP94-dependent tumor suppression, we used the
4T1 tumor model. 4T1 cells, derived from a spontaneous
mammary carcinoma of the BALB/c mouse, are highly ag-
gressive and metastasize widely (30). To ensure that the
cells used in the vaccination phase did not establish tumors,
cells were irradiated before injection into animals. As
shown in Fig. 3 A, irradiation did not compromise the abil-
ity of the cells to synthesize or secrete GRP94 KDEL.
To determine whether secretion of GRP94 could elicit
antitumor responses, mice were immunized with irradi-
ated, GRP94 KDEL-transfected 4T1 cells before chal-
lenge with viable 4T1 cells. In these experiments, control
groups were immunized with either PBS or irradiated,
mock-transfected 4T1 cells (4T1-mock). As expected,
mice in both control groups displayed rapid tumor growth
upon challenge with 4T1 tumor cells. Mock-transfected
4T1 cells were weakly immunogenic. The difference in tu-
mor volumes between the PBS-immunized and the 4T1-
mock–immunized groups was not, however, statistically
significant (P   0.33; Fig. 3, B, C, and G). In contrast,
mice immunized with GRP94 KDEL-secreting 4T1 cells
(4T1- KDEL) displayed a reduced rate of tumor growth
(Fig. 3, B, D, and G). The difference in tumor volumes be-
tween this group and the control groups was statistically
significant (P   0.00005 for PBS vs. 4T1- KDEL and P  
0.010 for 4T1-mock vs. 4T1- KDEL; Fig. 3 G).
Having established that prophylactic vaccination of mice
with irradiated, GRP94-secreting 4T1 cells was sufficient to
elicit tumor suppression, we examined the role of the
GRP94 KDEL cell host in the elicitation of tumor suppres-
sion. In one series of experiments, an allogenic fibroblast cell
line (NIH-3T3) was used as the vector cell host. Pulse-chase
studies comparing the relative GRP94 KDEL secretion ca-
pacities of 4T1 and NIH-3T3 cells revealed that both cell
types secreted similar levels of GRP94 KDEL (unpublished
data). Vaccination with irradiated, mock-transfected NIH-
Figure 3. Vaccination with 4T1 mammary carci-
noma cells or NIH-3T3 fibroblasts secreting
GRP94 KDEL leads to delayed tumor growth rates
and decreased tumor metastasis. (A) Irradiation does
not alter the secretion of GRP94 KDEL. 4T1 cells
were transfected with GRP94 KDEL (T and T/I) or
mock-transfected (mock). 24 h after transfection, cells
were irradiated with 10,000 rads (T/I) or left unirradi-
ated (T). 72 h after transfection, cells were metaboli-
cally labeled with [35S]Promix and GRP94 KDEL was
recovered from the media by immunoprecipitation.
Proteins were resolved by SDS-PAGE on 6% gels and
visualized by PhosphorImager analysis. (B–H)
GRP94 KDEL secretion from either 4T1 cells or
NIH-3T3 fibroblasts elicits delayed tumor growth.
Female BALB/c mice were immunized with PBS or
with irradiated, GRP94 KDEL-transfected or irradi-
ated, mock-transfected 4T1 or NIH-3T3 cells, as indi-
cated. Animals were then challenged with unirradiated
4T1 cells, as described in Materials and Methods, and
tumor volumes were followed over time. Tumor
growth curves for individual mice in each group are
shown in B–F and average tumor volumes with stan-
dard error are shown in G and H. (I) GRP94 KDEL
secretion from either 4T1 cells or NIH-3T3 fibroblasts
elicits decreased metastatic tumor progression. After
sacrifice, lungs were resected from mice in B–H and
weighed to determine the extent of metastatic tumor
burden. Average weights with standard error are
shown with groups differing significantly from PBS
control denoted by an asterisk (P   0.0012 for 4T1-
 KDEL and P   0.025 for NIH- KDEL). (J) Com-
parison of the relative levels of GRP94 KDEL secre-
tion by 4T1 and NIH-3T3 cells. Equal numbers (106
cells) of 4T1 or NIH3T3 cells were transfected with
GRP94 KDEL ( KDEL samples) or mock-transfected
(mock samples). 24 h after transfection, cells were meta-
bolically labeled with [35S]Promix and GRP94DKDEL
was recovered from the media by immunoprecipitation.
Proteins were resolved by SDS-PAGE on 6% gels and
visualized by PhosphorImager analysis.1452 GRP94 N-Terminal Domain Suppresses Tumor Growth and Metastasis
3T3 cells (NIH-mock) had little effect on subsequent 4T1 tu-
mor growth compared with PBS (P   0.57; Fig. 3, B, E, and
H). Unexpectedly, animals immunized with GRP94 KDEL-
secreting NIH-3T3 cells (NIH- KDEL) displayed signifi-
cantly reduced rates of tumor growth compared with control
animals (P   0.0013 for PBS vs. NIH- KDEL and P  
0.0022 for NIH-mock vs. NIH- KDEL; Fig. 3, F and H).
To examine the effects of vaccination on metastatic pro-
gression, animals were killed at the conclusion of the study
and their lungs were examined for evidence of distal tu-
mor metastasis. Lungs from control animals bore numer-
ous tumor nodules with far fewer nodules seen in
GRP94 KDEL-treated animals (unpublished data). Lung
weights were determined to quantify the extent of tumor
metastases (Fig. 3 I). Animals immunized with mock-trans-
fected 4T1 cells demonstrated slightly reduced lung
weights compared with PBS-immunized controls, al-
though this difference was not statistically significant
(P     0.070). In contrast, animals immunized with
GRP94 KDEL-secreting 4T1 cells displayed a signifi-
cantly reduced metastatic tumor burden (P   0.0012 for
PBS vs. 4T1- KDEL and P   0.010 for 4T1-mock vs.
4T1- KDEL). Similarly, lung tumor burden in mice im-
munized with GRP94 KDEL-transfected NIH-3T3 fi-
broblasts was significantly less than those of control mice
(P   0.025 for PBS vs. NIH- KDEL and P   0.026 for
NIH-mock vs. NIH- KDEL).
To compare the relative levels of GRP94 KDEL secre-
tion by 4T1 and NIH-3T3 cells, pulse-chase experiments
were performed (Fig. 3 J). The level of GRP94 KDEL se-
cretion by both cell types was comparable, indicating that
the tumor suppression observed after immunization with
GRP94-secreting fibroblasts does not result from an in-
creased GRP94 dose as compared with GRP94-secreting
4T1 cells.
A Role for GRP94 Structural Domains in DC Maturation
and Tumor Suppression. The previous experiments estab-
lished that vaccination of BALB/c mice with irradiated fi-
broblasts engineered to secrete GRP94 provided protection,
albeit incomplete, against subsequent challenge with 4T1
tumor cells. These findings suggested that GRP94-mediated
tumor suppression in this system was not tissue restricted.
Alternatively, and perhaps more likely, it was also consid-
ered that the GRP94 secreted from NIH-3T3 fibroblasts
was complexed with antigens common to 4T1 mammary
carcinoma cells, thereby eliciting anti-4T1 cellular immune
responses during the immunization stage. We used a protein
domain expression strategy to examine this possibility.
GRP94, the endoplasmic reticulum Hsp90 paralog, is com-
prised of three primary structural domains: an NH2-terminal
geldanamycin/adenosine nucleotide binding domain, a mid-
dle domain, and a COOH-terminal dimerization domain
(31–34). Previously, the putative peptide-binding domain
has been mapped to a COOH-terminal region adjacent to
the dimerization domain (35). In this study, we investigated
the GRP94 NH2-terminal domain. This domain has been
crystallized and as observed with Hsp90, displays a binding
pocket for adenosine nucleotides and the antitumor drugs
geldanamycin and radicicol (unpublished data). Importantly,
this domain lacks canonical peptide-binding motifs.
First, we examined the interaction of GRP94 NTD
with APC. As shown in Fig. 4 A, GRP94 NTD displayed
cell surface binding to bone marrow–derived DCs, elicited
peritoneal macrophages, and the macrophage-derived cell
line RAW264.7. Little or no binding of GRP94 NTD
was observed in B16-F10 melanoma cells, COS7 kidney
cells, or NIH-3T3 fibroblasts. Fluorescently labeled full-
length GRP94 similarly displayed binding to DCs, perito-
neal macrophages, and RAW264.7 cells with little to no
binding to B16-F10, COS7, or NIH-3T3 cells (11 and
unpublished data).
As a result of cell surface binding to APCs, GRP94 un-
dergoes receptor-mediated endocytosis (7–10, 13). To in-
vestigate the fate of cell surface–bound GRP94 NTD, fluo-
rescently labeled GRP94 or GRP94 NTD was first bound
to elicited peritoneal macrophages at 4 C. After binding,
unbound protein was removed by washing and the cells
were warmed to 37 C. In cells fixed before warming,
prominent cell surface binding of both GRP94 and the
GRP94 NH2-terminal domain was observed (Fig. 4 B, 0
min). After 10 min at 37 C, both GRP94 and GRP94
NH2-terminal domain gained entry to the cell as indicated
by a punctate intracellular peri-plasmalemmal staining pat-
tern (Fig. 4 B, 10 min). At longer incubation intervals,
GRP94 and GRP94 NH2-terminal domain were more
widely dispersed throughout the cell interior in prominent
vesicular structures. At each time point, full-length GRP94
colocalized with the GRP94 NH2-terminal domain (Fig. 4
B, Overlay). The internalization of GRP94 and GRP94
NH2-terminal domain was not interdependent. Both pro-
teins were internalized and displayed a similar trafficking
pattern in the absence of the other (unpublished data).
These observations indicate that the NH2-terminal domain
of GRP94 displays the pattern elements necessary for rec-
ognition and clearance by APCs.
GRP94 KDEL and GRP94 N-Terminal Domain Secreted
from NIH-3T3 Fibroblasts Elicit the Up-regulation of MHC
Class II and Costimulatory CD86 on DCs. It has previ-
ously been reported that GRP94 purified from normal
(nontumor) tissues elicits the up-regulation of MHC class
II molecules and costimulatory molecules such as CD86
(B7-2) in DCs (14, 15). To explore the biological rele-
vance of GRP94 NTD recognition by APCs, we exam-
ined whether the GRP94 NTD altered the expression of
cell surface markers on DCs.
DCs isolated on day 6 of culture displayed the following
characteristic phenotype: CD11c , MHC class II interme-
diate, GR-1 , CD80low, CD86low, CD40low (Fig. 5 A). As
expected, incubation of day 6 DCs for an additional 24 h in
media containing 100 ng/ml LPS produced the up-regula-
tion of MHC class II, CD80, CD86, and CD40 as com-
pared with incubation in media alone (Fig. 5 B). Incuba-
tion of DCs in conditioned media from mock-transfected
NIH-3T3 cells produced comparatively little up-regulation
of MHC class II, CD80, CD86, and CD40 (Fig. 5 B). No-
tably, exposure of day 6 DCs to conditioned media from1453 Baker-LePain et al.
GRP94 KDEL-transfected or GRP94 NTD-transfected
NIH-3T3 cells yielded the up-regulation of MHC class II
and CD86 expression with little effect on CD40 and CD80
expression (Fig. 5 B). This phenotypic pattern has been
previously described for exposure to full-length, tissue-
purified GRP94 (14, 15). These data indicate that secretory
forms of GRP94 and the GRP94 NH2-terminal domain
can recapitulate the function of GRP94 in the promotion
of DC maturation.
Immunization with GRP94 N-Terminal Domain Suppresses
4T1 Tumor Growth. The observation that the GRP94
NH2-terminal domain functioned similarly to the full-
length protein in assays of APC cell-surface binding, inter-
nalization, and DC maturation indicated that this domain
was biologically active. However, it was unknown whether
this domain would elicit antitumor immune responses. To
determine if the GRP94 NH2-terminal domain displayed
tumor suppression activity, 4T1 cells were transfected with
vector-encoding GRP94 NTD cDNA. After transfection,
the expression and secretion of a 36-kD protein reactive to
antibodies was raised against the NH2 terminus of GRP94
(Fig. 6 A). In contrast to results obtained with GRP94
 KDEL, GRP94 NTD was secreted as a single species, in-
dicating that this domain did not undergo the extensive
heterogeneous glycosylation observed for GRP94 KDEL
(Fig. 6 A).
In vivo tumor studies were performed using irradiated
4T1 cells expressing GRP94 NTD in the vaccination phase
(Fig. 6, B–F). As shown in Fig. 6, B–E, mice receiving im-
munizations of GRP94 NTD-transfected 4T1 cells dis-
played markedly smaller tumor size and slower tumor
growth rates than mice immunized with PBS or mock-
transfected cells (P    0.0002 for PBS vs. 4T1-GRP94
NTD and P    0.0006 for 4T1-mock vs. 4T1-GRP94
NTD; Fig. 6, B–E). In addition, animals immunized with
GRP94 NTD-secreting cells displayed significantly re-
duced lung tumor burden than control animals (P  
0.0031 for PBS vs. 4T1-GRP94 NTD and P   0.0008 for
4T1-mock vs. 4T1-GRP94 NTD).
To extend these observations, vaccination trials were
performed with haplotype-matched KBALB fibroblasts
transfected with GRP94 KDEL or GRP94 NTD cDNA.
The results of these studies are depicted in Fig. 7, where it
was observed that animals immunized with GRP94 NTD-
secreting KBALB cells displayed reduced primary tumor
burden than animals immunized with PBS or mock-trans-
Figure 4. GRP94 NH2-terminal domain is
cleared by APCs and colocalizes with full-
length GRP94 upon internalization. (A) Cell
type specificity of GRP94 NH2-terminal do-
main binding. Recombinantly expressed
GRP94 NH2-terminal domain was fluores-
cently labeled and used in a standard binding
assay with various cell types as described in Ma-
terials and Methods. The percentage of cells ex-
hibiting mean fluorescence above control is in-
dicated. (B) Clearance of GRP94 and GRP94
NH2-terminal regulatory domain by peritoneal
macrophages. Elicited peritoneal macrophages
were incubated with FITC-labeled GRP94
N-terminal domain (FITC-GRP94 NTD) and
TR-labeled full-length GRP94 (Texas Red-
GRP94). After washing at 4 C to remove un-
bound protein, cells were warmed to 37 C for
the indicated times before fixation and visual-
ization by confocal microscopy (100 ). The
overlay image displays dual channel imaging of
both labeled proteins.1454 GRP94 N-Terminal Domain Suppresses Tumor Growth and Metastasis
fected cells (P   0.0003 for PBS vs. KBALB-GRP94 KDEL,
P   0.0003 for PBS vs. KBALB-GRP94 NTD, and P   0.24
for PBS vs. KBALB-Mock; Fig. 7, A–E). In addition, animals
immunized with syngeneic fibroblasts secreting GRP94 KDEL
or GRP94 NTD had decreased metastatic tumor burden (P  
0.0003 for PBS vs. KBALB-GRP94 KDEL, P   0.0002 for
PBS vs. KBALB-GRP94 NTD, and P    0.8 for PBS vs.
KBALB-Mock; Fig. 7 F). Together, these observations demon-
strate that the NH2-terminal domain of GRP94 recapitulates
the activity of GRP94 KDEL in suppressing tumor growth
and metastatic progression.
To compare the relative levels of GRP94 KDEL and
GRP94 NTD secretion by 4T1 and KBALB cells, pulse-
chase experiments were performed (Fig. 7 G). The level of
GRP94 KDEL and GRP94 NTD secretion by both cell
types was comparable, indicating that the tumor suppres-
sion observed after immunization did not reflect differences
in GRP94 dose.
Tumor Histology. To gain insight into variations in the
tumor microenvironment among the vaccination groups in
the immunization and challenge protocol described above,
tumors from the control and experimental groups were ex-
cised at the time of sacrifice, fixed, and prepared for histo-
logical analysis (Fig. 8). In all cases, 4T1 tumors were char-
acterized by the predominance of malignant-appearing cells
with hyperchromatic nuclei and high nuclear to cytoplas-
mic ratios (unpublished data). Mitotic figures were abun-
dant and several atypical mitoses were observed, although
the mitotic rate did not differ significantly among the vari-
ous vaccination groups (unpublished data). The tumors fea-
tured large tracts of necrosis with obvious pyknosis and
karyolysis of nuclear material (Fig. 8). At the midpoint of
the study, tumors were characterized by the presence of
macrophages, neutrophils, and rare lymphocytes, although
the relative number of inflammatory cells did not differ
greatly among the various vaccination groups (unpublished
data). As seen at low power, tumors in control animals re-
ceiving vaccinations of PBS, mock-transfected 4T1 cells or
mock-transfected NIH-3T3 cells were larger in size and
contained larger areas of necrosis than tumors in animals re-
Figure 5. GRP94 KDEL and GRP94 N-ter-
minal domain elicit DC maturation. Condi-
tioned media from GRP94 KDEL-transfected,
GRP94 NTD-transfected, or mock-transfected
NIH-3T3 cells were collected for 72 h and in-
cubated with day 6 DCs as described in Materi-
als and Methods. (A) Phenotypic profile of day
6 DCs before incubation with conditioned me-
dia. (B) Phenotypic profile of day 7 DCs after
incubation with conditioned media from
mock-transfected, GRP94 KDEL-transfected,
or GRP94 NTD-transfected NIH-3T3 cells.
Incubation in media plus LPS was used as a pos-
itive control.1455 Baker-LePain et al.
ceiving vaccinations of GRP94 KDEL of GRP94 NTD-
transfected 4T1 or NIH-3T3 cells (Fig. 8).
Discussion
GRP94 can direct bound peptide antigens into the
MHC class I cross-presentation pathway and displays natu-
ral adjuvant activity in its interactions with APCs (1, 7, 10,
13–15). This study explores the contribution of GRP94-
bound antigens to the phenomenon of GRP94-mediated
tumor suppression. In the experiments described, engi-
neered GRP94/GRP94 domain-secreting cells served as
the source of GRP94 immunizing activity. We observed
that GRP94-mediated suppression of 4T1 tumor growth
and metastatic progression was not tissue restricted, i.e.,
GRP94 secreted from allogenic (NIH-3T3) and syngeneic
(KBALB) fibroblasts markedly inhibited the growth and
metastasis of 4T1 breast carcinoma cells. That the effects of
GRP94 were recapitulated by the GRP94 NTD, which
lacks canonical peptide binding motifs, suggests that phe-
nomenon other than peptide binding are of functional rele-
vance to GRP94-mediated tumor suppression.
The observation that GRP94-mediated tumor suppres-
sion can be independent of the tissue of GRP94 origin was
unexpected, particularly with respect to the broad literature
implicating GRP94-bound peptide antigens in GRP94-
elicited antitumor immune responses (1, 3, 10, 12). It has
recently been discovered, however, that heat shock/chap-
erone proteins including GRP94 can alter immune func-
tion independent of bound tumor antigen composition.
For example, GRP94 from nontumor sources elicits the
phenotypic maturation of cells with up-regulation of cell
surface costimulatory molecules and down-regulation of
GRP94 receptors (14, 15). In addition, GRP94 stimulates
IL-12, TNF- , and IL-1  secretion from macrophages and
DCs through activation of the NF- B signaling pathway
(14, 15). Such effects can be expected to influence the tu-
mor microenvironment and antitumor immune responses.
Thus, our data suggest that GRP94’s role in tumor sup-
pression may extend beyond the chaperoning of tumor
peptides to APCs. In this light, it is interesting to note that
GRP94 stimulation of CTL has been reported to occur re-
gardless of the identity of bound peptide antigens (36, 37).
In addition, in MHC class I–deficient Xenopus larvae,
GRP94 elicits profound antitumor responses in a tumor
antigen–independent manner (38).
As previously noted, and assuming that the two fibroblast
cell lines used in this study share common immunodomi-
nant peptide epitopes with the 4T1 carcinoma, the data
presented here remain compatible with models in which
the GRP94 NH2-terminal domain functions as a peptide
binding site in addition to its established activity as an aden-
Figure 6. Vaccination with 4T1 mammary
carcinoma cells secreting GRP94 NH2-terminal
domain leads to delayed tumor growth and de-
creased tumor metastasis. (A) Expression and se-
cretion of GRP94 NTD by transfected 4T1
cells. 4T1 cells were transfected with either
GRP94 KDEL or GRP94 NTD constructs or
were mock-transfected (mock) as indicated.
Cells were metabolically labeled with [35S]Pro-
mix, and GRP94 domains were recovered from
the media by immunoprecipitation before reso-
lution by SDS-PAGE. Radiolabeled proteins
were visualized by PhosphorImager analysis.
(B–E) GRP94 NTD elicits delayed tumor
growth rates. Female BALB/c mice were immu-
nized with PBS or with irradiated, GRP94
NTD-transfected or irradiated, mock-trans-
fected 4T1 cells as indicated. Animals were then
challenged with unirradiated 4T1 cells and tu-
mor volumes were followed over time, as de-
scribed in Fig. 3. Tumor growth curves for in-
dividual mice are shown in B–D and average
tumor volumes with standard error are shown
in E. GRP94 NTD elicits decreased metastatic
tumor progression. After animals were killed,
lungs were resected from mice in B–D and
weighed to determine the extent of metastatic
tumor burden. Average lung weights with stan-
dard error are shown with groups differing sig-
nificantly from PBS control denoted by an as-
terisk (P   0.00031).1456 GRP94 N-Terminal Domain Suppresses Tumor Growth and Metastasis
osine nucleotide, geldanamycin, and radicicol binding site
(33, 34). It should be considered, however, that recent
studies have localized a putative GRP94 peptide binding
site to the COOH terminus of the protein (35). In addi-
tion, crystallographic analyses of the Hsp90 NH2-terminal
adenosine nucleotide/geldanamycin binding domain did
not identify peptide binding motifs analogous to those of
Hsp70 chaperones, MHC class I or II molecules (33, 34,
35, 39). In addition, we report that the NH2-terminal do-
main of GRP94 binds to APCs and modulates the pheno-
typic profile of DCs, consistent with a natural adjuvant
function. Given these findings, we favor the interpretation
that GRP94 NH2-terminal domain function in tumor sup-
pression is independent of bound peptides. Nonetheless, it
remains formally possible that a previously uncharacterized
motif capable of binding peptides suitable for expression on
MHC class I resides in this domain. This possibility is un-
der continuing investigation.
The ability of GRP94 and other heat shock proteins to elicit
innate immune responses has recently been established (14–19).
Hsp60, for example, binds Toll-like receptor-4 on macro-
phages, eliciting NF- B signaling and the elaboration of TNF- ,
IL-12, and IL-15 (18, 19). Hsp60 also directly elicits the activa-
tion of cytotoxic T lymphocytes, as indicated by the induction
of interferon-  secretion in the absence of bound tumor anti-
gens (40). Similarly, Hsp70 binds to monocytes, initiating NF-
 B signaling and the secretion of TNF- , IL-1 , and IL-6 in a
manner that is independent of the presence of chaperoned tu-
mor antigen (16, 41, 42). In concert with these findings, it has
recently been reported that GRP94 plays a key role in the fold-
ing and cell surface presentation of toll-like receptor 2 and 4
and that GRP94-mediated activation of DCs occurs through
the same receptors (43, 44). Given the key role of toll-like re-
ceptors in the establishment of innate immune responses (20), it
is likely that these interactions play a role in GRP94-mediated
antitumor responses.
Figure 7. GRP94 KDEL and GRP94 NH2-
terminal domain secreted by syngeneic KBALB fi-
broblasts yield suppression of 4T1 tumor growth
and metastasis. Female BALB/c mice were immu-
nized with PBS or with irradiated, mock-trans-
fected, GRP94 KDEL-transfected, or GRP94
NTD-transfected KBALB fibroblasts as indicated.
Animals were then challenged with unirradiated
4T1 cells as described in Materials and Methods,
and tumor volumes were followed over time. Tu-
mor growth curves for individual mice in each
group are shown in A–D and average tumor vol-
umes with standard error are shown in E. (F)
GRP94 KDEL or GRP94 NH2-terminal domain
secretion from K-BALB fibroblasts yields decreased
tumor metastasis. After animals were killed, lungs
were resected from mice as shown in A–E and
weighed. Average weights with standard error are
shown, with groups differing significantly from
PBS control denoted by an asterisk (P   0.0003 for
KBALB- KDEL and P    0.0002 for KBALB-
NTD). (G) Comparison of GRP94 KDEL and
GRP94 NTD secretion by 4T1 and KBALB cells.
Equal numbers (106 cells) of 4T1 KBALB cells were
transfected with GRP94 KDEL ( KDEL sam-
ples), GRP94 NH2-terminal domain (NTD sam-
ples) or mock-transfected (mock samples). 24 h af-
ter transfection, cells were metabolically labeled
with [35S]Promix and GRP94 species were recov-
ered from the media by immunoprecipitation. Pro-
teins were resolved by SDS-PAGE on 12.5% gels
and visualized by PhosphorImager analysis.1457 Baker-LePain et al.
The precise immunological mechanism whereby GRP94
secreted from fibroblasts mediates antitumor responses remains
to be determined. To date, we have not detected the produc-
tion of anti-4T1 CTL after our immunization protocol with
GRP94-secreting fibroblasts (unpublished data), suggesting that
the different GRP94 donor cells used in our experiments do
not share common immunodominant antigens. Given recent
proposals for an NK and NK T cell function in the suppression
of tumor growth and metastasis and the demonstrations that in-
teractions between NK cells and DCs can play a primary role
in innate antitumor responses, it is tempting to speculate that
NK and/or NK T cell activity might be responsive to GRP94
immunization, and thereby contribute to GRP94-mediated
tumor suppression (45–51).
In mouse models of immunotherapy, a number of strategies
have proven effective in the suppression of tumor growth and
metastatic progression. Included in this growing list is the en-
hanced expression of cytokines (52, 53), costimulatory mole-
cules (54, 55), or MHC class I molecules (56, 57) within tumor
cells. It is likely that these strategies are effective by nature of
their ability to enhance both innate and adaptive immune re-
sponses. We envision the introduction of secretory forms of
GRP94, or the GRP94 NTD, to the animal as a similar vacci-
nation strategy. In addition to the utilization of secreted
GRP94–Fc fusion proteins (58), other novel approaches have
been taken to introduce chaperones/heat shock proteins to the
tumor microenvironment. For example, a transmembrane
form of GRP94 has been expressed in tumor cells and been
shown to elicit the maturation of DCs in vitro and tumor re-
gression in vivo (59). Overexpression of Hsp70 within tumors
has also been shown to result in tumor infiltration by DCs and
the expression of Th1-promoting cytokines (17). In this con-
text, secretion of heat shock proteins by cancer or noncancer
cells may prove to be a useful adjuvant therapy in the treatment
of cancer.
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